Regulatory Approval

« Back to Glossary Index

Regulatory Approval

Regulatory approval is a general industry phrase describing a regulator’s authorization to place a medical device on a market. The formal legal outcome and terminology vary by jurisdiction: in the United States, “approval” refers specifically to a PMA approval order under 21 CFR 814 (safety and effectiveness standard), while most Class II devices obtain 510(k) clearance under 21 CFR 807 by demonstrating substantial equivalence; De Novo classification is governed by 21 CFR 860. In the European Union, market access is via CE marking after conformity assessment to Regulation (EU) 2017/745 (MDR) or 2017/746 (IVDR)—this is not termed “approval.” Other systems use distinct outcomes (e.g., Canada device licences under the Medical Devices Regulations SOR/98-282; Australia inclusion in the ARTG; Japan shōnin approval or ninshō certification by PMDA/MHLW; UK UKCA marking per MHRA policy).

Jurisdiction-specificSafety & performanceMarket authorization

What regulators assess (high level)

  • Safety & effectiveness/performance demonstrated by valid scientific evidence appropriate to the pathway (e.g., PMA clinical data; MDR clinical evaluation).
  • Quality system readiness (e.g., U.S. QMSR/21 CFR 820 as aligned to ISO 13485; EU MDR QMS per Article 10).
  • Risk management, labeling/IFU, usability, cybersecurity, biocompatibility and other device-specific validations.
  • Post-market plans (e.g., PMS/PMCF in EU; post-approval studies or conditions in U.S. PMA, when required).

Terminology by jurisdiction (precise usage)

  • U.S. FDA (FD&C Act): PMA approval (21 CFR 814); 510(k) clearance (21 CFR 807 Subpart E); De Novo classification (21 CFR 860 Subpart D); EUA (emergency, 21 U.S.C. 360bbb-3; context-dependent).
  • European Union: CE marking after conformity assessment to MDR/IVDR (e.g., Annex IX–XI routes). Not termed “approval.”
  • Canada (Health Canada): Device licence (Classes II–IV) or establishment licence (Class I) per Medical Devices Regulations SOR/98-282.
  • Australia (TGA): Inclusion in ARTG per the Therapeutic Goods Act/Regs.
  • Japan (PMDA/MHLW): Shōnin approval (higher-risk) or ninshō certification (certain lower-risk) under the PMD Act.
  • United Kingdom (MHRA): UKCA marking (transition policies apply; status may be updated by MHRA guidance).

Common pitfalls and clarifications

  • “Approval” vs “clearance” (U.S.): Only PMA devices receive an approval order; 510(k) devices are cleared as substantially equivalent.
  • “Approval” vs “CE mark” (EU): EU grants market access via CE marking after conformity assessment; Member States do not “approve” devices under MDR/IVDR.
  • Regulatory vs reimbursement: Authorization to market (approval/clearance/CE mark) does not guarantee payer coverage or payment.
  • Change control: Significant changes often require new submissions (e.g., PMA supplements; MDR change assessments with Notified Body).

Quick checklist

  • Confirm the correct pathway/route for the target market (PMA, 510(k), De Novo; MDR Annex route; ARTG; device licence).
  • Align evidence: non-clinical + clinical mapped to intended use, indications, and risk.
  • Ensure QMS alignment (ISO 13485; U.S. QMSR alignment) and supplier controls.
  • Prepare labeling/IFU consistent with risk controls and claims.
  • Define post-market plan (PMS/PMCF, post-approval studies as applicable).

Regulatory Approval — FAQs

Does FDA “approval” apply to all devices?
No. In the U.S., approval refers to PMA devices (21 CFR 814). Most Class II devices receive 510(k) clearance (21 CFR 807); novel low-to-moderate-risk devices may use De Novo (21 CFR 860).
Is CE marking the same as approval?
No. CE marking indicates conformity to MDR/IVDR and allows EU market access; it is not termed “approval.”
Do I need a clinical study for approval?
It depends on the pathway and device risk. PMA typically requires clinical evidence of safety and effectiveness; EU MDR requires a clinical evaluation (Annex XIV) that may include clinical investigations depending on risk and claims.
Does authorization guarantee reimbursement?
No. Regulatory authorization enables marketing but does not establish payer coverage or payment; separate reimbursement pathways apply.
How are post-approval/CE-marked changes handled?
U.S.: PMA supplements or new 510(k)/De Novo, depending on change significance. EU: change assessment within the conformity assessment/QMS with the Notified Body; substantial changes may require updated certification.